Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2020 Dec 22;13(Suppl 1):S60-S64.
doi: 10.1093/inthealth/ihaa046.

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery

Gary J Weil  1 , Julie A Jacobson  2 , Jonathan D King  3
Affiliations
Multicenter Study

A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery

Gary J Weil et al. Int Health. .

Erratum in

Abstract

The Global Programme to Eliminate Lymphatic Filariasis (LF) is using mass drug administration (MDA) of antifilarial medications to treat filarial infections, prevent disease and interrupt transmission. Almost 500 million people receive these medications each year. Clinical trials have recently shown that a single dose of a triple-drug combination comprised of ivermectin, diethylcarbamazine and albendazole (IDA) is dramatically superior to widely used two-drug combinations for clearing larval filarial parasites from the blood of infected persons. A large multicenter community study showed that IDA was well-tolerated when it was provided as MDA. IDA was rapidly advanced from clinical trial to policy and implementation; it has the potential to accelerate LF elimination in many endemic countries.

Keywords: elimination; ivermectin; lymphatic filariasis; mass drug administration; therapy.

PubMed Disclaimer

References

    1. WHO . Progress report 2000–2009 and Strategic Plan 2010–2020 of the Global Programme to Eliminate Lymphatic Filariasis: Halfway Towards Eliminating Lymphatic Filariasis. Geneva: World Health Organization, 2010.
    1. Thomsen EK, Sanuku N, Baea Met al. . Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis. Clin Infect Dis. 2016;62(3):334–41. - PubMed
    1. King CL, Suamani J, Sanuku Net al. . A trial of a triple-drug treatment for lymphatic filariasis. N Engl J Med. 2018;379(19):1801–10. - PMC - PubMed
    1. King CL, Weil GJ, Kazura JW. Single-dose triple-drug therapy for Wuchereria Bancrofti: 5-year follow-up. New England Journal of Medicine. 2020;382(20):1956–7. - PMC - PubMed
    1. Bjerum CM, Ouattara AF, Aboulaye Met al. . Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in Cote d'Ivoire: an open-label, randomized, controlled trial. Clin Infect Dis. 2019. doi:10.1093/cid/ciz1050. - PMC - PubMed

Publication types

MeSH terms